Miller Investment Management LP Sells 28,982 Shares of VanEck Pharmaceutical ETF $PPH

Miller Investment Management LP reduced its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 15.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 152,936 shares of the company’s stock after selling 28,982 shares during the quarter. VanEck Pharmaceutical ETF makes up about 1.5% of Miller Investment Management LP’s holdings, making the stock its 16th biggest holding. Miller Investment Management LP’s holdings in VanEck Pharmaceutical ETF were worth $15,778,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in PPH. Royal Bank of Canada boosted its stake in shares of VanEck Pharmaceutical ETF by 53.3% during the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock valued at $6,160,000 after purchasing an additional 23,491 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of VanEck Pharmaceutical ETF by 7.3% during the 1st quarter. NewEdge Advisors LLC now owns 8,873 shares of the company’s stock valued at $809,000 after purchasing an additional 607 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of VanEck Pharmaceutical ETF by 13,856.9% during the 2nd quarter. Qube Research & Technologies Ltd now owns 16,190 shares of the company’s stock valued at $1,424,000 after purchasing an additional 16,074 shares in the last quarter. Raymond James Financial Inc. boosted its stake in shares of VanEck Pharmaceutical ETF by 11.8% during the 2nd quarter. Raymond James Financial Inc. now owns 22,417 shares of the company’s stock valued at $1,972,000 after purchasing an additional 2,363 shares in the last quarter. Finally, Two Sigma Securities LLC boosted its stake in shares of VanEck Pharmaceutical ETF by 40.1% during the 2nd quarter. Two Sigma Securities LLC now owns 4,480 shares of the company’s stock valued at $394,000 after purchasing an additional 1,282 shares in the last quarter.

VanEck Pharmaceutical ETF Trading Down 0.6%

Shares of PPH opened at $105.29 on Thursday. The firm’s 50-day moving average price is $102.91 and its 200-day moving average price is $104.29. The firm has a market capitalization of $999.20 million, a price-to-earnings ratio of 20.21 and a beta of 0.47. VanEck Pharmaceutical ETF has a 1-year low of $81.74 and a 1-year high of $112.58.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Wednesday, April 1st were paid a $0.8441 dividend. The ex-dividend date of this dividend was Wednesday, April 1st. This is a positive change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. This represents a $3.38 annualized dividend and a yield of 3.2%.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.